We understand that the sample size of our cohort could limit the statistical power potentially affecting the robustness and generalizability of our findings., however we manage to meat or primary goal and present a complete mutational panorama of early-stage prostate cancer patients, identifying a high frequency of mutations in NUP93 and CSMD3, the influence of mutational processes related to NHEJ DNA repair pathway in early-stage PRAD and the potential benefit of using PARP inhibitors in Mexican patients. The gene discussed is CSMD3; the disease is prostate adenocarcinoma.